ALKBH5 and breast cancer: According to a recent study (Yu et al., 2021), ALKBH5 could hinder the glycolytic pathway by reducing the stability of casein kinase 2 α(CK2 α) mRNA in an m6A-dependent manner, thus inhibiting the progression of BC and promoting BC cell sensitivity to cisplatin.